Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 13/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 9/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847423 | 0.91 | ITGAL (0.38) | ITGALITGB2ICAM1METAP2HSD11B1 | |
| SCHEMBL4848463 | 0.91 | HSD11B1 (0.37) | ITGALITGB2ICAM1METAP2HSD11B1 | |
| SCHEMBL4850402 | 0.90 | HSD11B1 (0.36) | ITGALITGB2ICAM1METAP2HSD11B1 | |
| SCHEMBL4850447 | 0.87 | MCHR1 (0.38) | ITGALITGB2ICAM1HSD11B1ELANE | |
| SCHEMBL4839926 | 0.86 | ITGAL (0.35) | ITGALITGB2ICAM1METAP2HSD11B1 | |
| SCHEMBL14264113 | 0.86 | TSHR (0.37) | ITGALITGB2ICAM1HSD11B1TMEM97 | |
| SCHEMBL16349444 | 0.86 | ITGAL (0.35) | ITGALITGB2ICAM1HSD11B1EBP | |
| SCHEMBL4848014 | 0.86 | METAP2 (0.36) | ITGALITGB2ICAM1METAP2CNR1 | |
| SCHEMBL4841707 | 0.85 | ITGAL (0.55) | ITGALITGB2ICAM1 | |
| SCHEMBL14254855 | 0.85 | ITGAL (0.46) | ITGALITGB2ICAM1METAP2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6897225-B1 | Inhibitors of αLβ2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | ITGAL 6/4885ITGB2 1/4885ICAM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.